PRELIMINARY AGENDA

Increasing Access to Essential Drugs in a Globalised Economy

Working Towards Solutions

From this page we will introduce links to the full text of the presentations made at the conference. Please check this page for updates. (last updated 14 April 2000)

Plenary Session I "Promoting access to essential drugs in a globalised economy"

Opening and Welcome by Austin Davis, General Director Médecins Sans Frontières, the Netherlands.

Full text in html

Strategies to increase access to essential drugs – a need for global commitment.

Mrs E. Herfkens, Minister of development cooperation, the Netherlands

Full text in html

The Messages of the 1999 Human Development Report - Globalization with a Human Face

Håkan Björkman, Human Development Report Office, United Nations Development Programme (UNDP), Denmark.

Full text in html.

International Trade Agreements and Public Health: WHO’s Role

Dr Gro Harlem Brundtland, Director-General, World Health Organization (presented by video)

Full text as Word document. / Full text in html.

Global trade agreements and public health - WHO's Role.

Dr Michael Scholtz. Executive Director HTP World Health Organization

(Full text as html document)

Intellectual property law and legal tools to increase access to essential medicines

Dr Carlos Correa, Universidad de Buenos Aires, Argentina.

(summary in html document) / (Related article in html)

Globalization and Access to Essential Drugs: Case Study from Thailand.

Dr. Suwit Wibulpolprasert. Editor, Human Resources for Health Development Journal, Thailand

(Full text in html)

Purchase pre-commitments for new vaccines: Rationale and a proposed design.

Dr. Michael Kremer, Harvard University USA.

Paper on Rationale: Full text as html document

Paper on Design: Full text as html document.

AIDS Activism - Putting access in developing countries on the agenda.

Asia Russell, ACT UP/ Philadelphia, USA and Zackie Achmat, Treatment Action C, South Africa.

Rountable I - Trade Related Issues of Promoting Access to Essential Medicines

Emerging issues in intellectual property and health,

James Love, Director, Consumer Project on Technology, USA

(Slide presentation)

Working Compulsory Licensing according to TRIPS - the Essential Drug Candidates

Pierre Chirac, Access to Essential Medicines, MSF

Compulsory licensing in practice: the South African case

Zackie Achmat, Treatment Action Campaign, South Africa

The Bolar Amendment and developing countries

Greg Perry, Director, European Generic Medicines Association, Belgium

The Parallel Pharmaceutical Trade: An Overview

John D. Barker, Chairman, Association of Pharmaceutical Importers, England

The brand name industry position

David Earnshaw, Head of the Brussels Office for Govermental Affairs and Public Policy, SmithKline Beecham, Belgium.

Full text in HTML

Roundtable II - Current Drug Pricing and Proposals for Change

Patents and Prices: the results of an international survey of drug prices

K. Balasubramaniam, International Coordinator Health Action International, Malaysia

Full text in html

Pricing Study - AZT

Catrin Schulte-Hillen, MSF, Spain

Full text in html / sheets in html

The price of azythromycine

Carmen Perez-Casas, MSF, Spain

Full text in html

The cost of treatment for Multi Drug Resistant TB

Jim Yong Kim, Partners in Health and Harvard Medical School

Presentation in ppt

Drug pricing: a global perspective

Marthe Everard, WHO, Department of Essential Drugs and Other Medicines

Evidence-Based Purchasing - Can we Create Buyers' Markets?

David Henry, Professor of Clinical Pharmacology, WHO Collaborating Centre for Training in Pharmacotherapy and Rational Drug Use, The University of Newcastle, NSW, Australia

Full text in html

Drug donations: an answer to market failure?

James Orbinski, MSF International, Brussels

Roundtable III - Promoting R&D for neglected diseases.

Strategies for promoting research and development for neglected diseases – an update on the debate.

Dr. Susan Foster, Boston University, USA and Dr. Bernard Pécoul, MSF.

Pushing and Pulling Technologies for the Poor.

Sarah England, Freelance Consultant

Full text in HTML.

The Role of Shin Poong Pharm.Co. for Parasite Control in Korea and other Developing Countries: the capacity of newly industrialised countries to carry out drug research and clinical testing.

Prof. Han-Jong Rim, President Korea Association of Health, Korea.

A case story: Treatment of Human African Trypanosomiasis (Sleeping Sickness): old drugs, expensive drugs and nothing new on the horizon.

Dr. Simon Gould, MSF.

Plenary Session II

Roundtable I : Trade Related Issues of Promoting Access to Essential Medicines

by Carolyn Green

Roundtable II : Current Drug Pricing and Proposals for Change

by Graham Dukes

Roundtable III : Promoting R&D for communicable and neglected diseases

by Catherine Hodgkin

Panel members:

Dr Jonathan Quick, Director Essential Drugs and Other Medicines Programme WHO, Geneva, Switzerland.

Adrian Otten, Director Intellectual Property & Investment division, World Trade Organisation, Geneva, Switzerland.

Ms. Nina Hvid, DG Trade, representative of the European Commission, Belgium

Summary in html

Dr. Giorgio Roscigno, Medical director region Middle-East Africa Hoechst Marion Roussel Inc., France.

Bernard Pécoul, MSF Project on Access to Essential Medicines

James Love, Director Consumer Project on Technology

Dr. K. Balasubramaniam, Coordinator Health Action International (Asia )

Closing by James Orbinski, President of the International Council MSF

Full text in html

Amsterdam Statement to WTO Member States on Access to Medicine

Full text in html